Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Generated: May 28, 2017

DrugPatentWatch Database Preview

IBANDRONATE SODIUM Drug Profile

« Back to Dashboard

What is the patent landscape for Ibandronate Sodium, and what generic Ibandronate Sodium alternatives are available?

Ibandronate Sodium is a drug marketed by Aurobindo Pharma Ltd, Watson Labs Inc, Apotex Inc, Sagent Pharms, Sun Pharm Inds Ltd, Accord Hlthcare, Mylan Labs Ltd, Emcure Pharms Ltd, Mylan Pharms Inc, Sun Pharm Inds, Dr Reddys Labs Ltd, and Orchid Hlthcare. and is included in fourteen NDAs.

The generic ingredient in IBANDRONATE SODIUM is ibandronate sodium. There are sixteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the ibandronate sodium profile page.

Summary for Tradename: IBANDRONATE SODIUM

Patents:0
Applicants:12
NDAs:14
Suppliers / Packagers: see list12
Bulk Api Vendors: see list129
Clinical Trials: see list948
Patent Applications: see list5,791
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:IBANDRONATE SODIUM at DailyMed

Pharmacology for Tradename: IBANDRONATE SODIUM

Ingredient-typeDiphosphonates
Drug ClassBisphosphonate
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma Ltd
IBANDRONATE SODIUM
ibandronate sodium
TABLET;ORAL204502-001Mar 11, 2016ABRXNoNo► Subscribe► Subscribe
Sun Pharm Inds Ltd
IBANDRONATE SODIUM
ibandronate sodium
INJECTABLE;INTRAVENOUS090853-001Feb 14, 2014APRXNoNo► Subscribe► Subscribe
Aurobindo Pharma Ltd
IBANDRONATE SODIUM
ibandronate sodium
INJECTABLE;INTRAVENOUS205332-001Aug 19, 2015APRXNoNo► Subscribe► Subscribe
Sun Pharm Inds
IBANDRONATE SODIUM
ibandronate sodium
TABLET;ORAL078996-001Aug 15, 2012ABRXNoNo► Subscribe► Subscribe
Accord Hlthcare
IBANDRONATE SODIUM
ibandronate sodium
INJECTABLE;INTRAVENOUS206058-001Feb 5, 2016APRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Identify first generic entrants

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot